Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin mucin 3 (TIM3) is a negative immune checkpoint and plays a crucial part in tumor-induced immune suppression. However, the mechanism of TIM3 in regulating immunosuppression in head and neck squamous cell carcinoma (HNSCC) was still not quite clear. We carried out the immunohistochemistry staining of HNSCC tissue microarrays. Through quantification of the histoscore, we performed the correlation analysis among the TIM3, Galectin-9, Foxp3, CD68 and CD163. The effects of TIM3 on regulatory T cells (Tregs) and macrophages were detected by utilizing the Tgfbr1/Pten 2cKO HNSCC mouse model. Flow cytometry were used to analysis the percent of Tregs, macrophages and IFN-γ. We demonstrated the close association among TIM3/Galectin-9 pathway, regulatory T cell marker (Foxp3) and macrophage marker (CD68, CD163) in human HNSCC. In the transgenic HNSCC mouse model, blockade of TIM3 by the anti-TIM3 monoclonal antibody induced a reduction of CD4 + CD25 + Foxp3 + Tregs. Meanwhile, the population of TIM3 + Tregs was also decreased. However, the population of CD206 + macrophages was not significantly declined. The increased IFN-γ production on CD8 + T cells in anti-TIM3 treatment mice showed that the antitumor immune response was enhanced through suppression of these negative immune factors. The present study demonstrated that TIM3 was associated with the immunosuppression in HNSCC. And targeting TIM3 can enhance anti-tumor immune response by decreasing Tregs in HNSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“tumor development by inhibiting tumor-specific immune response [11].”
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · cited 1×
“Regulatory T cell (Treg) is a subset of CD4 T cells and serves as an inhibitor of the antitumor immune response [6].”
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · cited 1×
“Although several molecules have been reported bind to TIM3 [16–18], Galectin-9 is considered as the major ligand [19].”
Frisancho-Kiss, S., Coronado, M. J., Frisancho, J. A., Lau, V. M., Rose, N. R., Klein, S. L., & Fairweather, D. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.12.002 · Cited by 143
Cited by
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Ruffin, A. T., Li, H., Vujanovic, L., Zandberg, D. P., Ferris, R. L., & Bruno, T. C. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00531-9 · Cited by 305
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“suggested that the interaction of MDSC-expressed Gal-9 and TIM-3 on Treg might drive MDSC expansion and suppressive activity [120], whereas a blockade of TIM-3 restored anti-tumor immunity by decreasing Treg numbers, their inhibitory capacity, and MDSC-mediated T cell inhibition [188].”
BackgroundResistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Metadata
- Authors
- Liu, J.-F., Wu, L., Yang, L.-L., Deng, W.-W., Mao, L., Wu, H., Zhang, W.-F., & Sun, Z.-J.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2018-03-05
- Volume
- 37
- Issue
- 1
- Pages
- 44-44
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2797220908
- Cited by
- 125
- References
- 6
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. https://app.cochat.ai/papers/10.1186/s13046-018-0713-7
- The paper
- Liu, J.-F., Wu, L., Yang, L.-L., Deng, W.-W., Mao, L., Wu, H., Zhang, W.-F., & Sun, Z.-J. (2018). Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-018-0713-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.